TCEB2 Antibody

What is TCEB2 protein and what cellular functions does it perform?

TCEB2 (Transcription Elongation Factor B Polypeptide 2) encodes Elongin B, a 13 kDa protein (observed at approximately 18 kDa on SDS-PAGE) that serves dual critical functions in cellular machinery. Primarily, it functions as a subunit of the transcription factor B (SIII) complex, which enhances RNA polymerase II-dependent elongation by suppressing transient pausing by the enzyme. Additionally, Elongin B acts as an adapter protein in the proteasomal degradation pathway, working with various E3 ubiquitin ligase complexes to facilitate targeted protein degradation . This dual functionality makes TCEB2 a significant target for studying both transcriptional regulation and protein quality control mechanisms.

What are the optimal applications for TCEB2 antibodies in molecular research?

TCEB2 antibodies have been validated for multiple applications with varying optimal dilutions:

For all applications, it is strongly recommended to perform antibody titration experiments to determine optimal conditions for specific experimental systems .

What is the significance of the discrepancy between calculated (13 kDa) and observed (18 kDa) molecular weights for TCEB2?

The discrepancy between the calculated molecular weight (13 kDa) and observed molecular weight (18 kDa) on SDS-PAGE gels is a documented phenomenon for TCEB2 . This difference may be attributed to several factors:

• Post-translational modifications (PTMs) such as phosphorylation, ubiquitination, or SUMOylation can increase apparent molecular weight

• The highly charged nature of some proteins can affect SDS binding, altering migration patterns

• Protein tertiary structure elements that resist complete denaturation

• Glycosylation or other modifications specific to certain cell types or conditions

This discrepancy is consistent across multiple antibody sources and should be considered a normal characteristic when validating TCEB2 antibody specificity. Researchers should expect to observe the 18 kDa band rather than the calculated 13 kDa band when performing Western blot analysis.

What are the critical factors for optimizing Western blot protocols with TCEB2 antibodies?

When optimizing Western blot protocols for TCEB2 detection, researchers should consider the following critical factors:

• Sample preparation:

  • Complete protease inhibition is essential to prevent TCEB2 degradation

  • Efficient cell lysis methods vary by cell type, with HEK-293, HeLa, and K-562 being well-documented positive controls

• Gel percentage:

  • 12-15% polyacrylamide gels provide optimal resolution for the 18 kDa TCEB2 protein

  • Consider gradient gels when also detecting TCEB2 interaction partners

• Transfer conditions:

  • Semi-dry transfer at 15V for 30 minutes or wet transfer at 100V for 1 hour

  • PVDF membranes typically perform better than nitrocellulose for this small protein

• Blocking and antibody dilution:

  • 5% non-fat dry milk in TBST is recommended for blocking

  • Antibody dilutions range from 1:500 to 1:10000 depending on specific antibody and application

  • Overnight incubation at 4°C often yields cleaner results than short incubations

• Signal detection:

  • Enhanced chemiluminescence (ECL) is sufficient for most applications

  • For quantitative analysis, consider digital imaging systems with extended dynamic range

Optimization of these parameters should be performed systematically, changing only one variable at a time.

How should immunoprecipitation experiments with TCEB2 antibodies be designed and executed?

Successful immunoprecipitation (IP) experiments with TCEB2 antibodies require careful consideration of several key parameters:

• Antibody amount and lysate ratio:

  • Use 0.5-4.0 μg antibody per 200-400 μg of whole cell extracts

  • HEK-293 cells have been validated as a positive control for TCEB2 IP experiments

• Lysis buffer composition:

  • Use mild non-denaturing lysis buffers containing 1% NP-40 or Triton X-100

  • Include protease inhibitors and phosphatase inhibitors if studying phosphorylation

  • Add 5 mM N-ethylmaleimide when studying ubiquitination pathways

• Pre-clearing strategy:

  • Pre-clear lysates with Protein A/G beads to reduce non-specific binding

  • Include an isotype control antibody (rabbit IgG) IP in parallel

• Co-IP considerations:

  • For studying TCEB2 interactions in transcription elongation complexes, consider crosslinking before lysis

  • For E3 ligase complex interactions, optimize salt concentration in wash buffers (150-300 mM NaCl)

• Elution and analysis:

  • Gentle elution with acidic glycine buffer preserves protein interactions

  • Denaturing elution with SDS sample buffer maximizes recovery for direct analysis

These protocols should be tailored based on the specific research question, particularly whether examining TCEB2's role in transcription or protein degradation pathways.

What validation methods should be employed to confirm TCEB2 antibody specificity?

Establishing antibody specificity is crucial for reliable research outcomes. For TCEB2 antibodies, employ these validation methods:

• Positive and negative controls:

  • Positive controls: HEK-293, HeLa, K-562, and HL-60 cells have confirmed TCEB2 expression

  • Species controls: Test across human and mouse samples to confirm cross-reactivity claims

  • Negative controls: Consider TCEB2 knockdown/knockout samples

• Molecular weight verification:

  • Confirm detection at 18 kDa (observed) rather than 13 kDa (calculated)

  • Run purified recombinant TCEB2 alongside samples for size comparison

• Cross-validation with multiple antibodies:

  • Compare results between different antibody clones targeting distinct epitopes

  • Verify localization patterns across different detection methods (WB, IHC, IF)

• Immunodepletion/competition assays:

  • Pre-incubate antibody with immunizing peptide/protein before application

  • Should result in signal reduction/elimination in true positive samples

• Peptide array analysis:

  • When available, test antibody against peptide arrays to confirm specific epitope recognition

  • Particularly important for polyclonal antibodies to assess potential cross-reactivity

Documented validation increases confidence in experimental results and should be reported in publications utilizing TCEB2 antibodies.

How does TCEB2 function differ in transcription elongation versus ubiquitin ligase complexes?

TCEB2 (Elongin B) exhibits dual functionality in cellular processes, with distinct protein interaction networks in each pathway:

• Transcription elongation (SIII complex):

  • Forms a heterotrimeric complex with Elongin A (TCEB3) and Elongin C (TCEB1)

  • Enhances RNA polymerase II transcription elongation rate by suppressing transient pausing

  • The structural integrity of this complex depends on proper TCEB2 folding and availability

  • Mutation or depletion affects global transcription rates, particularly for genes with pausing sites

• Ubiquitin ligase complexes:

  • Acts as an adapter protein in various E3 ubiquitin ligase complexes

  • Forms a structural scaffold with Elongin C to support substrate recognition

  • Interacts with Cullin proteins and VHL (von Hippel-Lindau tumor suppressor)

  • Critical for the ubiquitination and subsequent degradation of specific target proteins

This dual functionality makes TCEB2 a particularly interesting research target, as it links transcriptional regulation with protein quality control. Experimentally distinguishing between these functions requires careful consideration of binding partners and cellular compartments being studied.

What are effective troubleshooting strategies for inconsistent TCEB2 antibody results?

When encountering inconsistent results with TCEB2 antibodies, consider these systematic troubleshooting approaches:

• High background or non-specific binding:

  • Increase antibody dilution (1:5000-1:10000 for Western blot)

  • Optimize blocking conditions (try BSA instead of milk for phospho-specific detection)

  • Increase washing duration and number of washes

  • Pre-adsorb antibody with tissues/cells from non-target species

• Weak or no signal:

  • Decrease antibody dilution (1:500-1:2000 for Western blot)

  • Increase protein loading (50-100 μg total protein)

  • Optimize antigen retrieval for IHC (try both TE buffer pH 9.0 and citrate buffer pH 6.0)

  • Verify sample preparation maintains protein integrity with positive control antibodies

• Multiple bands or unexpected band sizes:

  • Validate with known positive controls (HEK-293, HeLa cells)

  • Consider post-translational modifications or degradation products

  • Increase gel percentage for better resolution of low molecular weight proteins

  • Compare results with multiple TCEB2 antibodies targeting different epitopes

• Inconsistent IP results:

  • Increase antibody amount (up to 4.0 μg per IP)

  • Optimize lysis conditions to preserve protein-protein interactions

  • Consider crosslinking before lysis for transient interactions

  • Adjust salt concentration in wash buffers (150-300 mM NaCl)

Detailed documentation of optimization steps will facilitate reproducibility and help identify the source of inconsistencies.

What experimental controls are essential when studying TCEB2 in various research models?

Robust experimental design for TCEB2 research requires these essential controls:

• Expression controls:

  • Positive control samples: HEK-293, HeLa, K-562, HL-60 cells, mouse skeletal muscle

  • Loading control: beta-actin, GAPDH, or total protein staining methods

  • Expression baseline: Untreated/unstimulated samples for comparison

• Antibody controls:

  • Isotype control (rabbit IgG) for immunoprecipitation experiments

  • Secondary antibody-only control to assess non-specific binding

  • Pre-immune serum control when available

• Genetic controls:

  • TCEB2 knockdown/knockout samples to validate antibody specificity

  • Overexpression systems with tagged TCEB2 for validation

  • Species-specific controls to confirm cross-reactivity claims

• Functional controls:

  • For transcription studies: RNA polymerase II inhibitors (α-amanitin)

  • For ubiquitination studies: Proteasome inhibitors (MG132, bortezomib)

  • For interaction studies: Known binding partners (TCEB1/Elongin C)

• Technical controls:

  • Biological replicates (minimum n=3) for statistical validity

  • Technical replicates to assess method reproducibility

  • Randomization and blinding for subjective analyses (e.g., IHC scoring)

Incorporating these controls ensures data reliability and facilitates troubleshooting when unexpected results occur.

How do different post-translational modifications affect TCEB2 antibody recognition?

Post-translational modifications (PTMs) can significantly impact antibody recognition of TCEB2, with implications for experimental design and interpretation:

• Phosphorylation effects:

  • Potential phosphorylation sites may alter epitope accessibility

  • Phosphatase treatment before Western blot can help identify phosphorylation-dependent recognition

  • Consider phospho-specific antibodies if studying TCEB2 regulation by kinases

• Ubiquitination considerations:

  • TCEB2's role in ubiquitin ligase complexes may lead to auto-ubiquitination

  • Multiple higher molecular weight bands may indicate ubiquitinated forms

  • Deubiquitinase treatment can confirm ubiquitin-dependent band patterns

• Other potential modifications:

  • SUMOylation may alter TCEB2 localization and function

  • Acetylation could affect protein-protein interactions

  • Oxidative modifications may occur under stress conditions

• Experimental approaches:

  • Use PTM-blocking agents in lysates to preserve specific modifications

  • Compare antibodies targeting different epitopes that may be differentially affected

  • Consider mass spectrometry validation of specific modifications

  • Include appropriate controls (phosphatase, deubiquitinase treatments)

Understanding the impact of PTMs on antibody recognition is particularly important when studying TCEB2 in different functional contexts or under various cellular stress conditions.

What are the optimal approaches for studying TCEB2 in immunohistochemistry applications?

When performing immunohistochemistry (IHC) with TCEB2 antibodies, consider these specialized approaches:

• Tissue preparation and fixation:

  • Formalin-fixed paraffin-embedded (FFPE) tissues are compatible with TCEB2 antibodies

  • Human colon cancer tissue has been validated as a positive control

  • Fixation time should be optimized (12-24 hours) to preserve epitope accessibility

• Antigen retrieval methods:

  • Heat-induced epitope retrieval (HIER) is essential

  • Primary recommendation: TE buffer at pH 9.0

  • Alternative approach: Citrate buffer at pH 6.0

  • Pressure cooker or microwave methods both effective

• Antibody concentration and incubation:

  • Recommended dilution range: 1:20-1:200

  • Begin optimization at 1:100 dilution

  • Overnight incubation at 4°C often yields optimal signal-to-noise ratio

• Detection systems:

  • Polymer-HRP detection systems provide good sensitivity

  • Consider tyramide signal amplification for low-abundance detection

  • DAB is the preferred chromogen for conventional brightfield microscopy

• Controls and validation:

  • Include known positive tissue controls (human colon cancer)

  • Use negative controls (isotype control antibody)

  • Consider dual staining with markers of known TCEB2-interacting proteins

Systematic optimization of these parameters will enable reliable TCEB2 detection in tissues for pathological studies or basic research applications.

How should co-immunoprecipitation experiments be designed to study TCEB2 protein interactions?

Co-immunoprecipitation (co-IP) experiments to study TCEB2 protein interactions require careful attention to preserve physiologically relevant complexes:

• Buffer composition for complex preservation:

  • For transcription complexes: Low stringency buffers (150 mM NaCl, 0.5% NP-40)

  • For ubiquitin ligase complexes: Include deubiquitinase inhibitors (NEM, PR-619)

  • Always include protease and phosphatase inhibitor cocktails

• IP antibody selection:

  • Use 0.5-4.0 μg TCEB2 antibody per experiment

  • Consider orientation: TCEB2 as bait vs. TCEB2 as prey

  • Alternative: Tag-based approaches using epitope-tagged TCEB2

• Common interaction partners to validate:

  • Transcription complex: TCEB1 (Elongin C), TCEB3 (Elongin A)

  • Ubiquitin ligase complex: Cullin2/5, VHL, SOCS proteins

  • RNA polymerase II components

• Technical considerations:

  • Pre-clearing lysates reduces background

  • Sequential IP can identify multi-protein complexes

  • Formaldehyde crosslinking (0.1%, 10 minutes) can stabilize transient interactions

  • Gentle elution preserves complex integrity for downstream analysis

• Analysis approaches:

  • Western blot for known/suspected partners

  • Mass spectrometry for unbiased identification

  • Functional validation through activity assays

These approaches enable comprehensive characterization of TCEB2's diverse protein interactions in different cellular contexts.

What experimental design considerations should be applied when using TCEB2 antibodies for dual-detection systems?

When implementing dual-detection systems involving TCEB2 antibodies, researchers should address these specialized considerations:

• Antibody compatibility in immunofluorescence:

  • Species compatibility: Choose primary antibodies from different host species

  • If both are rabbit-derived, consider direct labeling or sequential immunostaining

  • TCEB2 antibodies have been validated in immunofluorescence applications in U2OS cells

• Subcellular co-localization studies:

  • TCEB2 localizes predominantly to the nucleus but also appears in the cytoplasm

  • Select appropriate confocal parameters for high-resolution co-localization

  • Include co-localization coefficient calculations (Pearson's, Mander's)

• Proximity ligation assay (PLA) approaches:

  • Effective for detecting TCEB2 protein interactions in situ

  • Requires antibodies from different species or isotypes

  • Optimize antibody dilutions separately before combining (typically higher dilutions than standard IF)

• ChIP-Western/Re-ChIP applications:

  • For studying TCEB2 at specific genomic loci

  • Requires antibodies that work in both ChIP and Western blot

  • Consider epitope accessibility in crosslinked chromatin

• FRET/BRET experimental design:

  • For live-cell interaction studies

  • Tag position critical (N- vs C-terminus) based on TCEB2 structure

  • Controls must include non-interacting proteins with similar expression levels

These specialized detection approaches expand the analytical capabilities for studying TCEB2 beyond standard single-antibody applications and enable more sophisticated functional analyses.

How are TCEB2 antibodies being used to investigate emerging roles in cellular stress responses?

Recent research has expanded our understanding of TCEB2's functions beyond classical transcription and ubiquitination pathways, particularly in stress responses:

• Hypoxic stress responses:

  • TCEB2 forms complexes with HIF-1α through VHL during oxygen sensing

  • Antibody-based approaches revealing dynamic complex formation under varying oxygen conditions

  • Co-IP and proximity ligation assays demonstrating temporal regulation of these interactions

• DNA damage response pathways:

  • Emerging evidence for TCEB2 recruitment to sites of DNA damage

  • Methodological approaches combining TCEB2 antibodies with DNA damage markers

  • Potential ubiquitin ligase activities targeting DNA repair factors

• Cellular senescence mechanisms:

  • TCEB2 expression and localization changes during cellular senescence

  • Quantitative imaging approaches using validated antibodies to track senescence-associated redistribution

  • Co-localization with senescence markers providing functional insights

• Technical considerations:

  • Stress conditions may alter epitope accessibility

  • Controls must include matched stress conditions

  • Time-course experiments reveal dynamic regulation

  • Multiple antibody validation under stress conditions recommended

These emerging research areas highlight the importance of using well-characterized TCEB2 antibodies to elucidate novel functions beyond classical pathways.

What methodological advances are improving TCEB2 detection sensitivity and specificity?

Technological developments are enhancing TCEB2 detection capabilities in various experimental contexts:

• Signal amplification technologies:

  • Tyramide signal amplification (TSA) increasing detection sensitivity up to 100-fold

  • Quantum dot conjugated secondary antibodies providing improved signal-to-noise ratio

  • Proximity extension assays enabling ultra-sensitive detection in limited samples

• Multiplex detection systems:

  • Spectrally distinct fluorophores for simultaneous detection of TCEB2 and partners

  • Mass cytometry (CyTOF) approaches for single-cell protein interaction networks

  • Sequential immunofluorescence allowing numerous markers on single sections

• Super-resolution microscopy applications:

  • STORM/PALM techniques revealing nanoscale organization of TCEB2 complexes

  • Optimization protocols for antibody density and photoswitching buffers

  • Correlative light-electron microscopy linking molecular and ultrastructural data

• High-throughput screening platforms:

  • Automated IF/IHC systems enabling large-scale tissue analysis

  • Reverse phase protein arrays for quantitative profiling across sample sets

  • Antibody-based CRISPR screens for functional genomics

• In situ detection refinements:

  • RNAscope combined with IF for simultaneous RNA/protein detection

  • CODEX multiplexed imaging for tissue microenvironment characterization

  • Clearing-enhanced 3D imaging of thick tissue sections

These methodological advances provide researchers with expanded capabilities for studying TCEB2 across diverse experimental systems with improved sensitivity and specificity.